Company intelligence / Profile preview

Cellf BIO

Richmond, Virginia, United Statesseed.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

Cellf BIO has achieved a major milestone with the world’s first human implantation of its lead product, BioSphincter™, an autologous bioengineered sphincter made from smooth muscle and neural stem cells. The ongoing Phase 1 clinical trial is evaluating safety and initial efficacy for patients with severe passive fecal incontinence who have failed standard treatments. Early results indicate successful implantation and patient recovery, but full efficacy data are pending as the study continues.

Therapeutic areas: NephrologyGastroenterology
Modalities: Autologous cell therapy (using autologous progenitor and stem cells)Tissue engineering
Industry: Biotech

Drug pipeline

1 asset

BioSphincter

Partnerships

National Institutes of Health / NIDDK grant supportCSSi LifeSciences as CRO partner for IND filing support

Beyond the preview

Go deeper on Cellf BIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellf BIO.

Explore the full profile